Secukinumab for rheumatology: development and its potential place in therapy

Marije I Koenders
Wim B van den Berg
Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands

Abstract: Rheumatic disease is not a single disorder, but a group of more than 100 diseases that affect joints, connective tissues, and/or internal organs. Although rheumatic diseases like rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis (AS) differ in their pathogenesis and clinical presentation, the treatment of these inflammatory disorders overlaps. Non-steroid anti-inflammatory drugs are used to reduce pain and inflammation. Additional disease-modifying anti-rheumatic drugs are prescribed to slow down disease progression, and is in RA more frequently and effectively applied than in AS. Biologicals are a relatively new class of treatments that specifically target cytokines or cells of the immune system, like tumor necrosis factor alpha inhibitors or B-cell blockers. A new kid on the block is the interleukin-17 (IL-17) inhibitor secukinumab, which has been recently approved by the US Food and Drug Administration for moderate-to-severe plaque psoriasis, psoriatic arthritis, and AS. IL-17 is a proinflammatory cytokine that has an important role in host defense, but its proinflammatory and destructive effects have also been linked to pathogenic processes in autoimmune diseases like RA and psoriasis. Animal models have greatly contributed to further insights in the potential of IL-17 blockade in autoimmune and autoinflammatory diseases, and have resulted in the development of various potential drugs targeting the IL-17 pathway. Secukinumab (AIN457) is a fully human monoclonal antibody that selectively binds to IL-17A and recently entered the market under the brand name Cosentyx®. By binding to IL-17A, secukinumab prevents it from binding to its receptor and inhibits its ability to trigger inflammatory responses that play a role in the development of various autoimmune diseases. With secukinumab being the first in class to receive Food and Drug Administration approval, this article will further focus on this new biologic agent and review the milestones in its development and marketing.

Keywords: interleukin-17, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis

Introduction
Rheumatic diseases are characterized by pain and loss of function in one or more areas of the musculoskeletal system. It is not a single disorder, but a group of more than 100 diseases that affect joints; bones; cartilage; and connective tissues like tendons, ligaments, and muscles; they may also affect internal organs.

Arthritis (from Greek: arthros = joint, itis = inflammation) is one of the clinical manifestations of rheumatic diseases, and is characterized by pain, swelling, and stiffness of the affected synovial joints. Rheumatoid arthritis (RA) is the most common inflammation-driven rheumatic disease, which mainly affects the joints in a symmetrical manner and finally results in the destruction of cartilage and bone. This chronic autoimmune disease has been associated with genetic predisposition (eg, HLA-DR4, cytotoxic T-lymphocyte-associated antigen [CTLA]-4, and PTPN22) and environmental...
risk factors (eg, smoking and microorganisms), and is often accompanied by rheumatoid factor and anti-cyclic citrullinated protein antibodies as diagnostic and prognostic biomarkers for RA.\textsuperscript{1–3}

In contrast to RA, psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are considered seronegative rheumatic diseases; both PsA and AS are associated with genetic inheritance of the \textit{HLA-B27} gene.\textsuperscript{4,5} PsA is, like RA, also an inflammatory rheumatic disease characterized by arthritis and affects up to 30\% of patients with the chronic skin condition psoriasis.\textsuperscript{6} Its peripheral joint involvement may range from mild asymmetric joint inflammation to severe erosive arthritis. AS, formerly also known as Bechterew’s disease, is a rheumatic disease of the axial skeleton that mainly affects the spine and the sacroiliac joint in the pelvis. This spondyloarthropathy is characterized by erosion, sclerosis, and ossification, which may result in complete fusion and rigidity of the spine.\textsuperscript{7}

Despite the differences in pathogenesis and clinical presentation of RA, PsA, and AS, the treatment of these inflammatory rheumatic disorders is very overlapping. Nonsteroidal anti-inflammatory drugs are used to reduce pain and inflammation in rheumatic diseases; also, additional disease-modifying antirheumatic drugs, such as methotrexate (MTX) and sulfasalazine, are prescribed to slow down disease progression, and are more frequently and effectively applied in RA than in AS.\textsuperscript{8} Biologicals form a relatively new class of treatments that specifically target specific cytokines or cells in the immune system. The most frequently applied biological agents approved for RA, PsA, and AS are tumor necrosis factor alpha (TNF\(\alpha\)) inhibitors (including infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol).\textsuperscript{9,10} For RA, alternative and approved biologicals are directed against CTLA-4-driven T-cells (abatacept), CD20-expressing B-cells (rituximab), or the IL-6 receptor tocilizumab, and many new drugs are still in the pipeline.\textsuperscript{11–14}

However, alternatives for anti-TNF treatment failed to show efficacy in AS\textsuperscript{15,16} or are still in clinical trial for AS and PsA.\textsuperscript{17–19} PsA patients may also experience relief of symptoms by using the IL-12/IL-23 inhibitor ustekinumab, or by treatment with the synthetic disease-modifying antirheumatic drug phosphodiesterase-4 inhibitor apremilast, which is also being tested in other rheumatic diseases like AS.\textsuperscript{20–22}

A new kid on the block is the interleukin-17 (IL-17) inhibitor secukinumab, which has been recently approved by the US Food and Drug Administration (FDA) for moderate-to-severe plaque psoriasis, PsA, and AS\textsuperscript{23,24} (Figure 1). Secukinumab (AIN457) is a fully human monoclonal antibody that selectively binds to IL-17A and is now registered by Novartis International AG under the brand name

\textbf{Figure 1} Milestones in the development of the therapeutic anti-IL-17 antibody secukinumab.

\textbf{Abbreviations:} IL-17, interleukin 17; FDA, Food and Drug Administration; RA, rheumatoid arthritis; PsA, psoriatic arthritis; AS, ankylosing spondylitis; CTLA, cytotoxic T-lymphocyte-associated antigen; FIXTURE, Full Year Investigative Examination of Secukinumab vs Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis; ERASURE, Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis.
Cosentyx®. By binding to IL-17A, secukinumab prevents it from binding to its receptor and inhibits its ability to trigger inflammatory responses that play a role in the development of various autoimmune diseases.

**IL-17 and its biological function**

IL-17A is a proinflammatory cytokine that is a part of a family of six members (IL-17A to IL-17F). IL-17A, often referred to as IL-17, is a 17 kDa protein that is secreted as a dimer and was first described as CTLA-8 in the early nineties. IL-17 is mainly produced by a specific T-helper subset, the Th17 cell, although other immune cells like γδT-cells, natural killer cells, natural killer T-cells, innate lymphoid cells, neutrophils, and mast cells have also been described to express or produce this cytokine. Upon binding of IL-17 to its ubiquitously expressed receptor, IL-17RA pairs with IL-17RC to induce proinflammatory responses via TRAF6, ACT1, NF-κB, C/EBP, and MAPKs.

The existence of IL-17-producing CD4+ T-cells, Th17 cells, was only recently described after the discovery that the p40 subunit of IL-12 not only forms a heterodimer with IL-12p35, promoting interferon gamma-producing Th1 cells, but is also shared with IL-23p19. IL-23, together with tumor growth factor beta and IL-6, contributes to Th17 differentiation and survival under the control of transcription factor RORγ. Th17 cells are abundant at mucosal interfaces like the gut, where IL-17 plays an important function in the protection against extracellular bacterial and fungal infections by upregulation of cytokines and antimicrobial peptides and by recruitment of neutrophils.

In experimental studies, IL-17 was demonstrated to be required for host defense against *Klebsiella pneumoniae* infection in the lungs and *Citrobacter rodentium* infection in the gut. In patients suffering from the hyperimmunoglobulinemia E syndrome, an impaired IL-17 production by T-cells due to mutations in the *Stat3* gene has been identified as the main cause of a devastating susceptibility for common pathogens like *Staphylococcus aureus* and *Candida albicans*, resulting in recurrent and often severe pulmonary infections, mucocutaneous candidiasis, eczema, and staphylococcal abscesses. These findings and the recently described effects of modulating the microbiome on T-cell biology underscore the importance of Th17 responses in mucosal homeostasis and immunity.

**Target identification: IL-17 in rheumatic diseases**

Besides its role in immunity against infections, IL-17’s proinflammatory and destructive effects have also been linked to pathogenic processes in autoimmune diseases like RA, psoriasis, and PsA. Stimulation of synovial fibroblasts with IL-17 induces the expression of IL-6, IL-8, and matrix metalloproteinases, thereby promoting inflammation and cartilage destruction. In addition, IL-17 in synovial fluids from RA patients has been shown to induce the expression of RANKL, an essential mediator for osteoclastogenesis and bone resorption. Interestingly, IL-17 has been described to synergize with various proinflammatory cytokines, including TNFα, implicating an important inflammatory and catabolic function for IL-17 in disease pathogenesis.

In RA patients, increased systemic and local levels of this proinflammatory cytokine can be found. RA synovial tissue was found to spontaneously produce IL-17, and elevated levels of this cytokine have been reported in the synovial fluid of RA patients. Also in blood, increased IL-17 expression has been observed in patients with RA; besides increased cytokine levels in serum and IL-17+ CD4+ Th17 cells were found in blood from RA patients compared to healthy controls. Recent studies reported that IL-17/Th17 levels were surprisingly increased by anti-TNF treatment. Interestingly, in addition to CD4+ Th17 cells, CD8+ IL-17+ cytotoxic T-cells have been described in the synovial fluid of PsA patients, and this Tc17 cell was shown to positively correlate with various markers of disease severity.

In addition to the expression of IL-17, IL-17RC was also found to be upregulated in the synovial lining in PsA patients compared to osteoarthritis patients. For both PsA and AS, genome-wide association studies have identified polymorphisms of genes in the IL-17 pathway. PsA also has been associated with a polymorphism in the gene encoding for ACT1, a downstream signaling pathway of the IL-17 receptor.

Overall, IL-17 has been identified as a potential, interesting therapeutic target in RA, PsA, and AS, with further preclinical and clinical studies testing this hypothesis.

**Preclinical development of anti-IL-17 treatment**

Animal models have greatly contributed to further insights in the potential of IL-17 blockade in autoimmune and autoinflammatory diseases. Although animal models for PsA and AS are limited, many IL-17 inhibition studies have been performed in joint inflammation models resembling RA.

The complete absence of IL-17 in mice during collagen-induced arthritis development markedly suppressed disease onset as well as arthritis severity, and the effect of IL-17 deficiency was even more pronounced in the spontaneous...
Arthritis development in mice deficient of the IL-1 receptor antagonist, where disease was completely prevented. Another approach, knocking out the IL-17RA subunit followed by chronic reactivated streptococcal cell wall-induced arthritis, demonstrated the requirement of IL-17R signaling for sustained and destructive joint inflammation.

In contrast to complete absence of IL-17 signaling in transgenic mice, more refined inhibition of the IL-17 pathway in vivo models has been applied using neutralizing antibodies directed against this cytokine, or with soluble IL-17 receptors fused to an immunoglobulin fragment crystallizable (Fc)-domain to increase its circulation time. Blocking of endogenous IL-17 in the autoimmune collagen-induced arthritis model significantly reduced arthritis progression without affecting antigen-specific T- and B-cell responses, and even effective in established disease in IL-1RA-deficient mice. In reactivation of the murine antigen-induced arthritis model with local exposure to a small amount of methylated bovine serum albumin as antigen, flare of the joint inflammation and subsequent enhanced destruction could be completely prevented using anti-IL-17 treatment. Interestingly, the additive or synergistic effects of IL-17 with other cytokines were proven in murine collagen-induced arthritis, where blocking of IL-17 in combination with TNF or granulocyte macrophage colony stimulating factor more effectively reduced joint pathology than either treatment alone.

Although collagen-induced arthritis is considered one of the classical models for RA, the SKG mouse model may also present with features of spondyloarthritides, including AS and PsA. Upon systemic injection with beta-glucan, autoimmune-prone SKG mice with mutated ZAP-70 develop peripheral and axial arthritis, ileitis, and psoriasis-like skin inflammation. Reduced arthritis, spondylitis, and enthesitis in the absence of IL-17 or after treatment with IL-23 inhibitors also support the concept of IL-17 as a therapeutic target in these rheumatic diseases. This has finally led to the development of various IL-17 inhibitors: secukinumab and ixekizumab targeting IL-17 cytokines and brodalumab targeting IL-17RA. With secukinumab being the first in class to receive FDA approval, this article will further focus on this new biologic agent and review the milestones in its development and marketing (Figure 1).

**Safety profile of secukinumab**

The safety profile of secukinumab in various Phase II/III clinical trials on patients with rheumatic diseases was consistent with that observed with other biological therapies like etanercept. Most observed adverse events were mild to moderate in severity. Infections were more frequent with secukinumab than with placebo; nasopharyngitis or infections of the upper respiratory tract were most often reported. Some cases of mild-to-moderate candidiasis were reported, which resolved spontaneously or with oral therapy. Grade 2–3 neutropenia was reported in a couple of patients, although this was not associated with increased risk of infection. The occurrence of reported serious adverse events could not be directly...
linked to secukinumab treatment, and no deaths occurred. Overall, after several Phase II and III clinical trials in psoriasis and various rheumatic diseases with no unexpected safety signals and no specific organ-related toxicities, secukinumab is in general considered safe and well tolerated.

One important safety issue, however, should be mentioned here that is not directly associated with secukinumab but with the IL-17R-inhibitor brodalumab, which showed significant clinical improvements in patients with moderate-to-severe psoriasis in the AMAGINE-2 and AMAGINE-3 trials. Mid 2015, Amgen Inc. unexpectedly announced that it was discontinuing its co-development of brodalumab with AstraZeneca plc based on events of suicidal ideation and behavior in the brodalumab program. AstraZeneca plc claimed the observations of suicidal ideation and behavior are unlikely to be causally related to brodalumab therapy and is continuing full analysis of the AMAGINE studies. Without the exact details of these deaths in relation to their treatment, speculation on other confounding factors like a national surge in suicidality during the recent economic crisis, particularly affecting the study population in these trials, will not save the bad reputation of this IL-17R inhibitor. Despite all these, in January 2016, a Biologics License Application was submitted to the FDA by AstraZeneca plc in partnership with Valeant Pharmaceuticals, and a response is due by the end of the year.

Although secukinumab is far ahead of brodalumab in its clinical marketing and development, suicidality is not a reported issue during its clinical trials, the concerns raised by the brodalumab program may influence ongoing secukinumab programs and may put mental health of future secukinumab users under the microscope.

Therapeutic value of secukinumab in psoriasis

Before discussing the therapeutic value of secukinumab in rheumatic diseases, the impressive results of this anti-IL-17 antibody in the treatment of plaque psoriasis need to be mentioned here. Plaque psoriasis is a chronic inflammatory skin disease characterized by raised areas of inflamed skin covered with silvery-white scaly skin. After the first-in-man study with secukinumab already demonstrating highly significant effects on psoriasis severity, a Phase II, randomized, double-blind, placebo-controlled trial was performed on 125 patients with moderate-to-severe plaque psoriasis. Subcutaneous injections with secukinumab at 4-week intervals resulted in significantly higher PASI75 scores, indicating at least 75% improvement from baseline in the Psoriasis Area and Severity Index score: 82% in the 150 mg arm (P=0.001) and 57% in the 75 mg arm (P=0.002) versus 9% in the placebo group (Papp, BRD2013). This study was followed by several Phase III trials, which further confirmed and proved the clinical efficacy of this anti-IL-17 antibody in psoriasis. The ERASURE, FIXTURE, and FEATURE trials achieved their primary efficacy endpoint of PASI75 at week 12 with over 75% of the patients on 300 mg reaching PASI75 compared to <5% in the placebo controls (3REF), resulting in rapid FDA approval for secukinumab for its first indication: moderate-to-severe plaque psoriasis (Figure 1). Key trials with secukinumab in psoriasis and rheumatic diseases are summarized in Table 1, providing a quick overview of the study design and primary endpoints in various Phase II/III clinical trials.

Therapeutic value of secukinumab in RA

Phase I

In 2010, the combined results of three clinical trials on the safety and possible efficacy of secukinumab in RA, psoriasis, and chronic noninfectious uveitis were published. In the RA trial, 52 patients were enrolled (26 AIN457- and 26 placebo-treated patients) for a 16-week study with two infusions of AIN457 (10 mg/kg) at an interval of 3 weeks. Although the primary efficacy endpoint was not achieved, this study provided the first indications of clinical responses to secukinumab. The American College of Rheumatology 20% response (ACR20) rate expressed as area under the response-time curve was significantly higher in the secukinumab group than in the placebo control group, and this was also found for the 28-joint disease activity score (DAS28) and the serological inflammation marker C-reactive protein (CRP).

Phase II

In contrast to the impressive effects of anti-IL-17 treatment in psoriasis, published Phase II/III randomized controlled trials failed to demonstrate convincing data that secukinumab is effective in RA. The efficacy and safety of secukinumab were investigated in a double-blind, randomized, placebo-controlled Phase II study including 237 RA patients with inadequate response to MTX, who were randomly assigned to monthly subcutaneous injections of 25, 75, 150, or 300 mg secukinumab or placebo. At week 16, this resulted in ACR20 responses of 34.0%, 46.9%, 46.5%, and 53.7%, respectively, for the doses of secukinumab, compared to 36.0% in the placebo arm. However, these differences did not reach statistical significance, thereby failing to show clinical efficacy for secukinumab in RA. Although this primary
Table 1  Overview of the key randomized, double-blind, placebo-controlled clinical trials with secukinumab in psoriasis and rheumatic diseases

<table>
<thead>
<tr>
<th>Indication</th>
<th>Phase</th>
<th>Trial number</th>
<th>Patients</th>
<th>Dose (mg)</th>
<th>Primary endpoint</th>
<th>Met primary endpoint?</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pso</td>
<td>II</td>
<td>NCT01071252</td>
<td>125</td>
<td>25, 75, 150, PBO</td>
<td>PASI75 at week 12</td>
<td>Yes: 150 mg (82%, P&lt;0.001), 75 mg (57%, P=0.002), PBO (9%)</td>
<td>Papp et al(^{85})</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>NCT01365455</td>
<td>738</td>
<td>150, 300, PBO</td>
<td>PASI75 at week 12</td>
<td>Yes: 300 mg (81.6%), 150 mg (71.6%), PBO (4.5%) (P&lt;0.001)</td>
<td>Langley et al(^{74})</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>NCT01358578</td>
<td>1,306</td>
<td>150, 300, PBO, ETA</td>
<td>PASI75 at week 12</td>
<td>Yes: 300 mg (77.1%), 150 mg (67.0%), ETA (44.0%), PBO (4.9%) (P&lt;0.001)</td>
<td>Langley et al(^{74})</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>NCT01555125</td>
<td>177</td>
<td>150, 300, PBO</td>
<td>PASI75 at week 12</td>
<td>Yes: 300 mg (75.9%), 150 mg (69.5%), PBO (0%) (P&lt;0.0001)</td>
<td>Blauvelt et al(^{86})</td>
</tr>
<tr>
<td>RA</td>
<td>II</td>
<td>NCT00928512</td>
<td>237</td>
<td>25, 75, 150, 300, PBO</td>
<td>SC monthly</td>
<td>No: 25–300 mg (36.0%–53.7%) vs PBO (34%)</td>
<td>Genovese et al(^{75,78})</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>NCT00809614</td>
<td>42</td>
<td>10 mg/kg, PBO</td>
<td>ACR20 at week 6</td>
<td>No: 10 mg/kg (39%) vs PBO (23%) (P=0.27)</td>
<td>Novartis Pharmaceuticals(^{90})</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>NCT01392326</td>
<td>606</td>
<td>150, 300, PBO</td>
<td>ACR20 at week 24</td>
<td>Yes: 150 mg (50.0%), 75 mg (50.5%), PBO (17.3%) (P&lt;0.001)</td>
<td>Mease et al(^{76})</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>NCT01752634</td>
<td>397</td>
<td>75, 150, 300, PBO</td>
<td>ACR20 at week 24</td>
<td>Yes: 300 mg (54%, P&lt;0.0001), 150 mg (51%, P&lt;0.0001), 75 mg (29%, P=0.0399) vs PBO (15%)</td>
<td>McInnes et al(^{77})</td>
</tr>
<tr>
<td>PsA</td>
<td>II</td>
<td>NCT01392326</td>
<td>606</td>
<td>150, 300, PBO</td>
<td>ACR20 at week 6</td>
<td>Yes: 10 mg/kg (59%) vs PBO (24%), Bayesian probability 99.8%</td>
<td>Baeten et al(^{93})</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>NCT01752634</td>
<td>397</td>
<td>75, 150, 300, PBO</td>
<td>ASAS20 at week 16</td>
<td>Yes: 10 IV → 75 SC (59.7%) and 10 IV → 75 SC (60.8%) vs PBO (28.7%) (P&lt;0.01)</td>
<td>Baeten et al(^{76,78})</td>
</tr>
<tr>
<td>AS</td>
<td>II</td>
<td>NCT00809159</td>
<td>30</td>
<td>10 mg/kg, PBO</td>
<td>ASAS20 at week 6</td>
<td>Yes: 10 mg/kg (59%) vs PBO (24%), Bayesian probability 99.8%</td>
<td>Baeten et al(^{93})</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>NCT01358175</td>
<td>371</td>
<td>10 mg/kg IV → 75 or 150</td>
<td>ASAS20 at week 16</td>
<td>No: 10 IV → 75 SC (59.7%) and 10 IV → 150 SC (60.8%) vs PBO (28.7%) (P&lt;0.01)</td>
<td>Braun et al(^{79})</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>NCT01649375</td>
<td>219</td>
<td>75, 150, PBO</td>
<td>SC 4 weeks apart</td>
<td>Yes: 150 mg (61.1%, P&lt;0.0001), 75 mg (41.1%, NS) vs PBO (28.4%)</td>
<td>Baeten et al(^{79})</td>
</tr>
</tbody>
</table>

Abbreviations: Pso, psoriasis; PBO, placebo; SC, subcutaneous; ETA, etanercept; RA, rheumatoid arthritis; ACR20, American College of Rheumatology 20% response; PsA, psoriatic arthritis; IV, intravenous; AS, ankylosing spondylitis; ASAS20, 20% Assessment of SpondyloArthritis international Society; NS, nonsignificant; FIXTURE, Full Year Investigative Examination of Secukinumab vs Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis; ERASURE, Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis.
efficacy endpoint of significant ACR20 responses at 16 weeks was not achieved, beneficial effects of the secukinumab doses 75, 150, and 300 mg were observed on DAS28–CRP scores.75 When evaluating the long-term safety and efficacy in a follow-up study till 52 weeks, RA patients responding to secukinumab in the first 16 weeks showed a sustained clinical response, or even further improvement in their response rates up to week 52.87 A recent Phase II biomarker study investigating the association of HLA-DRB1 alleles with clinical response to secukinumab was actually the first and only study to demonstrate the clinical efficacy of secukinumab over a placebo arm in RA with significantly better ACR20 response rates (87.1% in the secukinumab group vs 25.0% in the placebo group) and reduced DAS28–CRP at week 12,89 although no association was found between the HLA-DRB1*04 allele and response to secukinumab treatment. Current data from a limited set of Phase II trials are not convincing, and evidence for the efficacy of secukinumab in RA from a proper Phase III trial is still lacking. Preclinical research using the human RA synovium SCID mouse model demonstrated that anti-IL-17 was only effective when the synovial tissue was rich in CD3+ T-cells,88 suggesting that determining the T-cell dominance in RA patients using a set of biomarkers might help to predict the responsiveness to secukinumab treatment.

Phase III
Various Phase III studies on secukinumab in RA have recently been completed (eg, NCT01350804 and NCT01640938) or are still in progress (NCT01901900 and NCT01770379).89,90 More information will be obtained in the next few years on the clinical efficacy of this anti-IL-17 inhibitor in RA patients on MTX or with an inadequate response to anti-TNF agents. These results will yield a final verdict on the efficacy of secukinumab in RA and will further define the potential clinical utility of this treatment in patients with RA.

Application of secukinumab in PsA
Compared to RA, clinical trials on secukinumab for the treatment of PsA are much further in progress, and Novartis International AG filed a regulatory application for secukinumab as a PsA drug in the US and EU in Q2 2015. A Phase II proof-of-concept trial in 42 patients with active PsA did not meet its primary endpoint of ACR20 response at week 6, with ACR20 response in 39% of patients for secukinumab versus 23% for placebo (P=0.27), although significant improvement in the acute-phase proteins CRP and erythrocyte sedimentation rate (ESR) and quality of life as secondary endpoints suggested some clinical benefit from secukinumab treatment in PsA.91 Recent results from the randomized, placebo-controlled Phase III FUTURE 1 and 2 trials (NCT01392326 and NCT01752634) indicate that secukinumab is indeed an efficacious treatment for patients with PsA.76,77 FUTURE 1 included 606 PsA patients randomly assigned to intravenous secukinumab followed by subcutaneous treatment with this IL-17 blocker at two different doses (150 or 300 mg), or placebo, and resulted in impressive and significant improvement in ACR20 and the American College of Rheumatology 50% response (ACR50), as well as two psoriasis area and severity indexes (PASI75 and PASI90) as secondary outcome parameters.76 FUTURE 2 had a slightly different design with 397 PsA patients receiving subcutaneous injections of either placebo or secukinumab 75, 150, or 300 mg once a week for 4 weeks, continued every 4 weeks.77 Also in this Phase III trial, the primary efficacy endpoint was met for all the secukinumab doses, as secukinumab treatment clearly improved the signs and symptoms of PsA; with secukinumab 300 mg, 54% of the patients achieved ACR20 at week 24 versus 51% with 150 mg, 29% with 75 mg, and 15% with placebo.77 In line with this impressive effect on the primary endpoint, for the doses 75 and 150 mg, significant effects were reported on various secondary endpoints, including PASI75 and PASI90, DAS28–CRP, and ACR50. Interestingly, clinical response rates were generally higher in anti-TNF-naïve patients than in anti-TNF inadequate responders, with the low-dose (75 mg) secukinumab group failing to show significant ACR20 and ACR50 responses to secukinumab treatment upon stratification.77 Overall, these FUTURE trials have build an impressive record on the efficacy of secukinumab in PsA, resulting in the European and US FDA approval for secukinumab for PsA, together with the approval for AS, in November 2015 and January 2016, respectively.24,92

Treatment of AS
As already mentioned, the European Medicines Agency and FDA have approved secukinumab for the treatment of AS since multiple clinical trials have demonstrated its positive findings in AS. To test the safety and efficacy of secukinumab in AS, a randomized, double-blind, placebo-controlled Phase II trial was performed among 30 patients with moderate-to-severe AS.93 Secukinumab administered intravenously 3 weeks apart was well tolerated and clinically efficacious, as convincingly demonstrated by improved 20% Assessment of SpondyloArthritis international Society response rates at week 6 (59.2% with secukinumab vs 24.5%
with placebo), with Bayesian analysis indicating a probability of 99.8% of secukinumab inducing greater response rates than placebo. A follow-up study demonstrated a sustained clinical response in the majority of these AS patients when secukinumab was continued at 3 mg/kg every 4 weeks until week 94, which was accompanied by regression of inflammatory spinal lesions as assessed by magnetic resonance imaging. Recent results of the Phase III MEASURE 1 and 2 trials (NCT01358175 and NCT01649375) presented at the ACR conferences in Boston (2014) and San Francisco (2015) confirmed that secukinumab resulted in rapid and significant improvement of signs and symptoms in patients with active AS, with ~61% of the patients in the 150 mg secukinumab arms showing 20% Assessment of SpondyloArthritis international Society response at week 16 compared to 28% in the placebo arms. Data from both the MEASURE trials also indicated that secukinumab was associated with a reduction of spinal inflammation as assessed by magnetic resonance imaging, as in ~80% of the patients treated with secukinumab for 104 weeks no radiographic progression was observed. Other Phase III trials are ongoing to provide even more evidence on long-term safety and efficacy of secukinumab in AS (NCT02008916, NCT01863732, and NCT02159053), with results expected in 2017/2018.

Other rheumatic diseases: Behçet’s disease

A 24-week, randomized, double-blinded, placebo-controlled Phase III trial was conducted in 118 Behçet’s patients with posterior uveitis or panuveitis to assess the difference in the rate of recurrent exacerbations when treated with secukinumab versus placebo adjunctive to standard-of-care immunosuppressive therapy. This trial (NCT00995709) failed to demonstrate clinical improvement and showed a similar rate of recurrent ocular exacerbations during 24 weeks of treatment. Additional trials investigating the efficacy of secukinumab in (Behçet’s) uveitis were halted (eg, NCT01093846, NCT01032915, NCT01090310, and NCT01103024) or withdrawn (NCT01327664).

Secukinumab in Crohn’s disease

Expectations were high when anti-IL-17 treatment was recently tested in Crohn’s disease (CD), but it results in dramatic failure of both secukinumab as well as AMG 827 for this indication. The multicenter Phase II trial on secukinumab in 59 patients with established moderate-to-severe CD was prematurely terminated. Secukinumab did not help in improving CD; moreover, worsening of the disease was reported as reflected in the high rate of serious adverse events as well as fungal infections. It seems that the role of IL-17 in diseases like CD has to be revisited, as more and more studies have discovered the protective effects of IL-17 at mucosal sites, important for host defense and immune homeostasis together with other Th17 cytokines like IL-22.

Secukinumab in autoinflammatory syndromes

In contrast to autoimmune diseases with a dysregulated adaptive immune system, autoinflammatory syndromes like familial Mediterranean fever and TNF receptor-associated periodic syndrome are caused by an exaggerated innate immune system response resulting in episodes of spontaneous inflammation affecting multiple organs. This major difference in pathogenesis also affects the type of treatments applied; rather than anti-TNF, CTLA-4-Ig, or B-cell-based biologicals, corticosteroids or anti-IL-1 treatment are most frequently applied. Many autoinflammatory diseases are linked to a dysfunctional caspase-1 activity and increased secretion of IL-1β by monocytes/macrophages, and the blocking of IL-1β has resulted in dramatic improvement in various autoinflammatory diseases. As the role of T-cells like Th17 cells in the pathogenesis of this type of inflammations is minimal or absent, the potential of secukinumab treatment in autoinflammatory disease will be only based on IL-17 production by innate immune cells and is therefore expected to be very limited.

Conclusion: potential place in therapy

After demonstrating great clinical efficacy in psoriasis, secukinumab received its first global approval in Japan on Boxing Day 2014 for the treatment of psoriasis and PsA. The secukinumab US regulatory application for moderate-to-severe plaque psoriasis was filed in October 2013, with subsequent FDA recommendation in October 2014 and final FDA approval granted on January 21, 2015. Regulatory approval for secukinumab for the indications of AS and PsA was recently obtained in Europe and the US at the end of 2015/early 2016. Depending on the outcome of Phase III trials on secukinumab in RA, this may be followed by filing for RA in the coming years, although it must be stressed that convincing clinical efficacy data for secukinumab in RA are still lacking and most likely will not show similar efficacy as demonstrated in other rheumatic diseases such as PsA and AS. With secukinumab entering the market, international
treatment guidelines for various rheumatic diseases may need to be updated, giving this IL-17 inhibitor as first in a novel class of drugs a position and ranking between the current available treatments for patients with various inflammatory rheumatic diseases.

Acknowledgment
This work was sponsored by the Innovative Medicines Initiative Joint Undertaking funded project BT Cure (grant number: agreement 115142-2).

Disclosure
The authors report no conflicts of interest in this work.

References


89. Novartis Pharmaceuticals. Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents (REASSURE). Available from: https://clinicaltrials.gov/ct2/show/NCT01377012


